Oral delivery of biomacromolecules by overcoming biological barriers in the gastrointestinal tract: an update

References

• Urquhart L. Top companies and drugs by sales in 2022. Nat Rev Drug Discov. 2023;22(4):260. doi: 10.1038/d41573-023-00039-3
   PubMed Web of Science ®Google Scholar
• Cao SJ, Xu S, Wang HM, et al. Nanoparticles: oral delivery for protein and peptide drugs. AAPS Pharm Sci Tech. 2019;20(5):190. doi: 10.1208/s12249-019-1325-z
   PubMed Web of Science ®Google Scholar
• Brayden DJ, Hill TA, Fairlie DP, et al. Systemic delivery of peptides by the oral route: formulation and medicinal chemistry approaches. Adv Drug Deliv Rev. 2020;157:2–36.
   PubMed Web of Science ®Google Scholar
• Chen G, Kang W, Li W, et al. Oral delivery of protein and peptide drugs: from non-specific formulation approaches to intestinal cell targeting strategies. Theranostics. 2022;12(3):1419–1439. doi: 10.7150/thno.61747
   PubMed Web of Science ®Google Scholar
• Drucker DJ. Advances in oral peptide therapeutics. Nat Rev Drug Discov. 2020;19(4):277–289. doi: 10.1038/s41573-019-0053-0
   PubMed Web of Science ®Google Scholar
• Cui Z, Qin L, Guo S, et al. Design of biotin decorated enterocyte targeting muco-inert nanocomplexes for enhanced oral insulin delivery. Carbohydr Polym. 2021;261:117873. doi: 10.1016/j.carbpol.2021.117873
   PubMed Web of Science ®Google Scholar
• Cheng H, Cui Z, Guo S, et al. Mucoadhesive versus mucopenetrating nanoparticles for oral delivery of insulin. Acta Biomater. 2021;135:506–519. doi: 10.1016/j.actbio.2021.08.046
   PubMed Web of Science ®Google Scholar
• Li J, Qiang H, Yang W, et al. Oral insulin delivery by epithelium microenvironment-adaptive nanoparticles. J Control Release. 2022;341:31–43. doi: 10.1016/j.jconrel.2021.11.020
   PubMed Web of Science ®Google Scholar
• Duran-Lobato M, Lopez-Estevez AM, Cordeiro AS, et al. Nanotechnologies for the delivery of biologicals: historical perspective and current landscape. Adv Drug Deliv Rev. 2021;176:113899. doi: 10.1016/j.addr.2021.113899
   PubMed Web of Science ®Google Scholar
• Moroz E, Matoori S, Leroux JC. Oral delivery of macromolecular drugs: where we are after almost 100 years of attempts. Adv Drug Deliv Rev. 2016;101:108–121.
   PubMed Web of Science ®Google Scholar
• Ahadian S, Finbloom JA, Mofidfar M, et al. Micro and nanoscale technologies in oral drug delivery. Adv Drug Deliv Rev. 2020;157:37–62. doi: 10.1016/j.addr.2020.07.012
   PubMed Web of Science ®Google Scholar
• Liu C, Kou Y, Zhang X, et al. Strategies and industrial perspectives to improve oral absorption of biological macromolecules. Expert Opin Drug Deliv. 2018;15(3):223–233. doi: 10.1080/17425247.2017.1395853
   PubMed Web of Science ®Google Scholar
• Zhu Q, Chen Z, Paul PK, et al. Oral delivery of proteins and peptides: challenges, status quo and future perspectives. Acta Pharm Sin B. 2021;11(8):2416–2448. doi: 10.1016/j.apsb.2021.04.001
   PubMed Web of Science ®Google Scholar
• Goldberg M, Gomez-Orellana I. Challenges for the oral delivery of macromolecules. Nat Rev Drug Discov. 2003;2(4):289–295. doi: 10.1038/nrd1067
   PubMed Web of Science ®Google Scholar
• Han Y, Gao Z, Chen L, et al. Multifunctional oral delivery systems for enhanced bioavailability of therapeutic peptides/proteins. Acta Pharm Sin B. 2019;9(5):902–922. doi: 10.1016/j.apsb.2019.01.004
   PubMed Web of Science ®Google Scholar
• Jiang L, Sun Y, Lu A, et al. Ionic liquids: promising approach for oral drug delivery. Pharm Res. 2022;39(10):2353–2365. doi: 10.1007/s11095-022-03260-8
   PubMed Web of Science ®Google Scholar
• Elsayed A, Al-Remawi M, Jaber N, et al. Advances in buccal and oral delivery of insulin. Int J Pharm. 2023;633:122623. doi: 10.1016/j.ijpharm.2023.122623
   PubMedGoogle Scholar
• Guo F, Lin L, He Z, et al. Storage stability of soy protein isolate powders containing soluble protein aggregates formed at varying pH. Food Sci Nutr. 2020;8(10):5275–5283. doi: 10.1002/fsn3.1759
   PubMed Web of Science ®Google Scholar
• Bryant C, Spencer DB, Miller A, et al. Acid stabilization of insulin. Biochemistry. 1993;32(32):8075–8082. doi: 10.1021/bi00083a004
   PubMed Web of Science ®Google Scholar
• Ryu K-W, Na D-H. Stability of octreotide acetate in aqueous solutions and PLGA films. J Korean Pharm Sci. 2009;39(5):353–357. doi: 10.4333/KPS.2009.39.5.353
   Google Scholar
• Estey T, Kang J, Schwendeman SP, et al. BSA degradation under acidic conditions: a model for protein instability during release from PLGA delivery systems. J Pharm Sci. 2006;95(7):1626–1639. doi: 10.1002/jps.20625
   PubMed Web of Science ®Google Scholar
• Sun Y, Wang M, Sun B, et al. An investigation into the gastrointestinal stability of exenatide in the presence of pure enzymes, everted intestinal rings and intestinal homogenates. Biol Pharm Bull. 2016;39(1):42–48. doi: 10.1248/bpb.b15-00442
   PubMed Web of Science ®Google Scholar
• Iyer G, Dyawanapelly S, Jain R, et al. An overview of oral insulin delivery strategies (OIDS). Int j biol macromol. 2022;208:565–585. doi: 10.1016/j.ijbiomac.2022.03.144
   PubMed Web of Science ®Google Scholar
• Gedawy A, Martinez J, Al-Salami H, et al. Oral insulin delivery: existing barriers and current counter-strategies. J Pharm Pharmacol. 2018;70(2):197–213. doi: 10.1111/jphp.12852
   PubMed Web of Science ®Google Scholar
• Moughan PJ, Rutherfurd SM, Montoya CA, et al. Food-derived bioactive peptides–a new paradigm. Nutr Res Rev. 2014;27(1):16–20. doi: 10.1017/S0954422413000206
   PubMed Web of Science ®Google Scholar
• Wang J, Yadav V, Smart AL, et al. Toward oral delivery of biopharmaceuticals: an assessment of the gastrointestinal stability of 17 peptide drugs. Mol Pharm. 2015;12(3):966–973. doi: 10.1021/mp500809f
   PubMed Web of Science ®Google Scholar
• Klepach A, Tran H, Ahmad Mohammed F, et al. Characterization and impact of peptide physicochemical properties on oral and subcutaneous delivery. Adv Drug Deliv Rev. 2022;186:114322. doi: 10.1016/j.addr.2022.114322
   PubMed Web of Science ®Google Scholar
• Bernkop-Schnurch A. The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins. J Control Release. 1998;52(1–2):1–16. doi: 10.1016/S0168-3659(97)00204-6
   PubMed Web of Science ®Google Scholar
• Wang F, Sangfuang N, McCoubrey LE, et al. Advancing oral delivery of biologics: machine learning predicts peptide stability in the gastrointestinal tract. Int J Pharm. 2023;634:122643. doi: 10.1016/j.ijpharm.2023.122643
   PubMedGoogle Scholar
• Pechenov S, Revell J, Will S, et al. Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease. Sci Rep. 2021;11(1):22521. doi: 10.1038/s41598-021-01750-0
   PubMed Web of Science ®Google Scholar
• McShane A, Bath J, Jaramillo AM, et al. Mucus. Curr Biol. 2021;31(15):R938–R945. doi: 10.1016/j.cub.2021.06.093
   PubMed Web of Science ®Google Scholar
• Padhye T, Maravajjala K, Swetha KL, et al. A comprehensive review of the strategies to improve oral drug absorption with special emphasis on the cellular and molecular mechanisms. J Drug Delivery Sci Technol. 2021;61:61. doi: 10.1016/j.jddst.2020.102178
   Web of Science ®Google Scholar
• Haddadzadegan S, Dorkoosh F, Bernkop-Schnurch A. Oral delivery of therapeutic peptides and proteins: technology landscape of lipid-based nanocarriers. Adv Drug Deliv Rev. 2022;182:114097. doi: 10.1016/j.addr.2021.114097
   PubMed Web of Science ®Google Scholar
• Zhang JY, Liu XX, Lin JY, et al. Biomimetic engineered nanocarriers inspired by viruses for oral-drug delivery. Int J Pharm. 2022;624:121979. doi: 10.1016/j.ijpharm.2022.121979
   PubMedGoogle Scholar
• Wang X, Sherman A, Liao G, et al. Mechanism of oral tolerance induction to therapeutic proteins. Adv Drug Deliv Rev. 2013;65(6):759–773. doi: 10.1016/j.addr.2012.10.013
   PubMed Web of Science ®Google Scholar
• Ouyang J, Zhang ZY, Deng B, et al. Oral drug delivery platforms for biomedical applications. Mater Today. 2023;62:296–326. doi: 10.1016/j.mattod.2023.01.002
   Web of Science ®Google Scholar
• Camenisch G, Alsenz J, van de Waterbeemd H, et al. Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur J Pharm Sci. 1998;6(4):317–324. doi: 10.1016/S0928-0987(97)10019-7
   PubMed Web of Science ®Google Scholar
• Sharma A, Vaghasiya K, Ray E, et al. Lysosomal targeting strategies for design and delivery of bioactive for therapeutic interventions. J Drug Target. 2018;26(3):208–221. doi: 10.1080/1061186X.2017.1374390
   PubMed Web of Science ®Google Scholar
• Yun Y, Cho YW, Park K. Nanoparticles for oral delivery: targeted nanoparticles with peptidic ligands for oral protein delivery. Adv Drug Deliv Rev. 2013;65(6):822–832. doi: 10.1016/j.addr.2012.10.007
   PubMed Web of Science ®Google Scholar
• Tomita M, Shiga M, Hayashi M, et al. Enhancement of colonic drug absorption by the paracellular permeation route. Pharm Res. 1988;5(6):341–346. doi: 10.1023/A:1015999309353
   PubMed Web of Science ®Google Scholar
• Doak BC, Over B, Giordanetto F, et al. Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates. Chem Biol. 2014;21(9):1115–1142. doi: 10.1016/j.chembiol.2014.08.013
   PubMed Web of Science ®Google Scholar
• Lopes M, Shrestha N, Correia A, et al. Dual chitosan/albumin-coated alginate/dextran sulfate nanoparticles for enhanced oral delivery of insulin. J Control Release. 2016;232:29–41. doi: 10.1016/j.jconrel.2016.04.012
   PubMed Web of Science ®Google Scholar
• Mazumdar S, Chitkara D, Mittal A. Exploration and insights into the cellular internalization and intracellular fate of amphiphilic polymeric nanocarriers. Acta Pharm Sin B. 2021;11(4):903–924. doi: 10.1016/j.apsb.2021.02.019
   PubMed Web of Science ®Google Scholar
• Lu W, Tian H, Qian P, et al. An orally available hypoglycaemic peptide taken up by caveolae transcytosis displays improved hypoglycaemic effects and body weight control in db/db mice. Br J Pharmacol. 2020;177(15):3473–3488. doi: 10.1111/bph.15069
   PubMed Web of Science ®Google Scholar
• Damm EM, Pelkmans L, Kartenbeck J, et al. Clathrin- and caveolin-1-independent endocytosis: entry of simian virus 40 into cells devoid of caveolae. J Cell Bio. 2005;168(3):477–488. doi: 10.1083/jcb.200407113
   PubMed Web of Science ®Google Scholar
• Pan Y, Zheng JM, Zhao HY, et al. Relationship between drug effects and particle size of insulin-loaded bioadhesive microspheres. Acta Pharmacol Sin. 2002;23(11):1051–1056.
   PubMed Web of Science ®Google Scholar
• Czuba E, Diop M, Mura C, et al. Oral insulin delivery, the challenge to increase insulin bioavailability: influence of surface charge in nanoparticle system. Int J Pharm. 2018;542(1–2):47–55. doi: 10.1016/j.ijpharm.2018.02.045
   PubMed Web of Science ®Google Scholar
• Managuli RS, Raut SY, Reddy MS, et al. Targeting the intestinal lymphatic system: a versatile path for enhanced oral bioavailability of drugs. Expert Opin Drug Deliv. 2018;15(8):787–804. doi: 10.1080/17425247.2018.1503249
   PubMed Web of Science ®Google Scholar
• Jin CH, Chae SY, Son S, et al. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice. J Control Release. 2009;133(3):172–187. doi: 10.1016/j.jconrel.2008.09.091
   PubMed Web of Science ®Google Scholar
• Ohlsson L, Kohan AB, Tso P, et al. GLP-1 released to the mesenteric lymph duct in mice: effects of glucose and fat. Regul Pept. 2014;189:40–45. doi: 10.1016/j.regpep.2014.02.001
   PubMedGoogle Scholar
• Soudry-Kochavi L, Naraykin N, Nassar T, et al. Improved oral absorption of exenatide using an original nanoencapsulation and microencapsulation approach. J Control Release. 2015;217:202–210. doi: 10.1016/j.jconrel.2015.09.012
   PubMed Web of Science ®Google Scholar
• Deng F, Bae YH. Bile acid transporter-mediated oral drug delivery. J Control Release. 2020;327:100–116. doi: 10.1016/j.jconrel.2020.07.034
   PubMed Web of Science ®Google Scholar
• Nemati M, Fathi-Azarbayjani A, Al-Salami H, et al. Bile acid-based advanced drug delivery systems, bilosomes and micelles as novel carriers for therapeutics. Cell Biochem Funct. 2022;40(6):623–635. doi: 10.1002/cbf.3732
   PubMed Web of Science ®Google Scholar
• Zhang Z, Li H, Xu G, et al. Liver-targeted delivery of insulin-loaded nanoparticles via enterohepatic circulation of bile acids. Drug Deliv. 2018;25(1):1224–1233. doi: 10.1080/10717544.2018.1469685
   PubMed Web of Science ®Google Scholar
• Pang H, Huang X, Xu ZP, et al. Progress in oral insulin delivery by PLGA nanoparticles for the management of diabetes. Drug Discov Today. 2023;28(1):103393. doi: 10.1016/j.drudis.2022.103393
   PubMed Web of Science ®Google Scholar
• Tuvia S, Pelled D, Marom K, et al. A novel suspension formulation enhances intestinal absorption of macromolecules via transient and reversible transport mechanisms. Pharm Res. 2014;31(8):2010–2021. doi: 10.1007/s11095-014-1303-9
   PubMed Web of Science ®Google Scholar
• Tran H, Aihara E, Mohammed FA, et al. In vivo mechanism of action of sodium caprate for improving the intestinal absorption of a GLP1/GIP coagonist peptide. Mol Pharmaceut. 2023;20(2):929–941. doi: 10.1021/acs.molpharmaceut.2c00443
   PubMedGoogle Scholar
• Fattah S, Ismaiel M, Murphy B, et al. Salcaprozate sodium (SNAC) enhances permeability of octreotide across isolated rat and human intestinal epithelial mucosae in Ussing chambers. Eur J Pharm Sci. 2020;154:105509. doi: 10.1016/j.ejps.2020.105509
   PubMed Web of Science ®Google Scholar
• Dahlgren D, Olander T, Sjoblom M, et al. Effect of paracellular permeation enhancers on intestinal permeability of two peptide drugs, enalaprilat and hexarelin, in rats. Acta Pharm Sin B. 2021;11(6):1667–1675. doi: 10.1016/j.apsb.2020.12.019
   PubMed Web of Science ®Google Scholar
• Welling SH, Hubalek F, Jacobsen J, et al. The role of citric acid in oral peptide and protein formulations: relationship between calcium chelation and proteolysis inhibition. Eur J Pharm Biopharm. 2014;86(3):544–551. doi: 10.1016/j.ejpb.2013.12.017
   PubMed Web of Science ®Google Scholar
• Alama T, Kusamori K, Morishita M, et al. Mechanistic studies on the absorption-enhancing effects of gemini surfactant on the intestinal absorption of poorly absorbed hydrophilic drugs in rats. Pharmaceutics. 2019;11(4):170. doi: 10.3390/pharmaceutics11040170
   PubMed Web of Science ®Google Scholar
• McCartney F, Rosa M, Brayden DJ. Evaluation of sucrose laurate as an intestinal permeation enhancer for macromolecules: ex vivo and in vivo studies. Pharmaceutics. 2019;11(11):565. doi: 10.3390/pharmaceutics11110565
   PubMed Web of Science ®Google Scholar
• McCartney F, Jannin V, Chevrier S, et al. Labrasol(r) is an efficacious intestinal permeation enhancer across rat intestine: ex vivo and in vivo rat studies. J Control Release. 2019;310:115–126. doi: 10.1016/j.jconrel.2019.08.008
   PubMed Web of Science ®Google Scholar
• Lin PY, Chuang EY, Chiu YH, et al. Safety and efficacy of self-assembling bubble carriers stabilized with sodium dodecyl sulfate for oral delivery of therapeutic proteins. J Control Release. 2017;259:168–175. doi: 10.1016/j.jconrel.2016.12.018
   PubMed Web of Science ®Google Scholar
• Kim JC, Park EJ, Na DH. Gastrointestinal permeation enhancers for the development of oral peptide pharmaceuticals. Pharmaceuticals (Basel). 2022;15(12):1585. doi: 10.3390/ph15121585
   PubMedGoogle Scholar
• Mori S, Matsuura A, Rama Prasad YV, et al. Studies on the intestinal absorption of low molecular weight heparin using saturated fatty acids and their derivatives as an absorption enhancer in rats. Biol Pharm Bull. 2004;27(3):418–421. doi: 10.1248/bpb.27.418
   PubMed Web of Science ®Google Scholar
• Padula C, Pescina S, Nicoli S, et al. New insights on the mechanism of fatty acids as buccal permeation enhancers. Pharmaceutics. 2018;10(4):201. doi: 10.3390/pharmaceutics10040201
   PubMed Web of Science ®Google Scholar
• Wang L, Li L, Sun Y, et al. In vitro and in vivo evaluation of chitosan graft glyceryl monooleate as peroral delivery carrier of enoxaparin. Int J Pharm. 2014;471(1–2):391–399. doi: 10.1016/j.ijpharm.2014.05.050
   PubMed Web of Science ®Google Scholar
• Wang L, Sun Y, Shi C, et al. Uptake, transport and peroral absorption of fatty glyceride grafted chitosan copolymer-enoxaparin nanocomplexes: influence of glyceride chain length [Article]. Acta Biomater. 2014;10(8):3675–3685. doi: 10.1016/j.actbio.2014.05.003
   PubMed Web of Science ®Google Scholar
• Maher S, Mrsny RJ, Brayden DJ. Intestinal permeation enhancers for oral peptide delivery. Adv Drug Delivery Rev. 2016;106(Null). doi: 10.1016/j.addr.2016.06.005
   PubMedGoogle Scholar
• Fein KC, Gleeson JP, Cochran K, et al. Long‐term daily oral administration of intestinal permeation enhancers is safe and effective in mice. Bioengineering Transla Med. 2022;8(1): doi: 10.1002/btm2.10342
   PubMed Web of Science ®Google Scholar
• Kommineni N, Sainaga Jyothi VGS, Butreddy A, et al. SNAC for enhanced oral bioavailability: an updated review. Pharm Res. 2023;40(3):633–650. doi: 10.1007/s11095-022-03459-9
   PubMedGoogle Scholar
• Twarog C, Fattah S, Heade J, et al. Intestinal Permeation enhancers for oral delivery of macromolecules: a comparison between Salcaprozate Sodium (SNAC) and Sodium Caprate (C(10)). Pharmaceutics. 2019;11(2):78. doi: 10.3390/pharmaceutics11020078
   PubMed Web of Science ®Google Scholar
• Alani AW, Robinson JR. Mechanistic understanding of oral drug absorption enhancement of cromolyn sodium by an amino acid derivative. Pharm Res. 2008;25(1):48–54. doi: 10.1007/s11095-007-9438-6
   PubMed Web of Science ®Google Scholar
• Weng H, Hu L, Hu L, et al. The complexation of insulin with sodium N‐[8‐(2‐hydroxybenzoyl)amino]‐caprylate for enhanced oral delivery: effects of concentration, ratio, and pH. Chin Chem Lett. 2022;33(4):1889–1894. doi: 10.1016/j.cclet.2021.10.023
   Web of Science ®Google Scholar
• Brown TD, Whitehead KA, Mitragotri S. Materials for oral delivery of proteins and peptides. Nature Rev Mater. 2019;5(2):127–148. doi: 10.1038/s41578-019-0156-6
   Web of Science ®Google Scholar
• Ukai H, Kawagoe A, Sato E, et al. Propylene glycol caprylate as a novel potential absorption enhancer for improving the intestinal absorption of insulin: efficacy, safety, and absorption-enhancing mechanisms. J Pharm Sci. 2020;109(4):1483–1492. doi: 10.1016/j.xphs.2019.12.012
   PubMed Web of Science ®Google Scholar
• Azman M, Sabri AH, Anjani QK, et al. Intestinal absorption study: challenges and absorption enhancement strategies in improving oral drug delivery. Pharmaceuticals. 2022;15(8):975. doi: 10.3390/ph15080975
   Web of Science ®Google Scholar
• Yewale C, Patil S, Kolate A, et al. Oral absorption promoters: opportunities, issues, and challenges. Crit Rev Ther Drug Carrier Syst. 2015;32(5):363–387. doi: 10.1615/CritRevTherDrugCarrierSyst.2015011865
   PubMed Web of Science ®Google Scholar
• Bao X, Qian K, Yao P. Insulin- and cholic acid-loaded zein/casein-dextran nanoparticles enhance the oral absorption and hypoglycemic effect of insulin. J Mater Chem B. 2021;9(31):6234–6245. doi: 10.1039/D1TB00806D
   PubMed Web of Science ®Google Scholar
• Tran H, ElSayed MEH. Progress and limitations of oral peptide delivery as a potentially transformative therapy. Expert Opin Drug Deliv. 2022;19(2):163–178. doi: 10.1080/17425247.2022.2051476
   PubMed Web of Science ®Google Scholar
• Su FY, Lin KJ, Sonaje K, et al. Protease inhibition and absorption enhancement by functional nanoparticles for effective oral insulin delivery. Biomaterials. 2012;33(9):2801–2811. doi: 10.1016/j.biomaterials.2011.12.038
   PubMed Web of Science ®Google Scholar
• Zhang D, Wang J, Xu D. Cell-penetrating peptides as noninvasive transmembrane vectors for the development of novel multifunctional drug-delivery systems. J Control Release. 2016;229:130–139. doi: 10.1016/j.jconrel.2016.03.020
   PubMed Web of Science ®Google Scholar
• Kristensen M, Nielsen HM. Cell-penetrating peptides as carriers for oral delivery of biopharmaceuticals. Basic Clin Pharmacol Toxicol. 2016;118(2):99–106. doi: 10.1111/bcpt.12515
   PubMed Web of Science ®Google Scholar
• Yang L, Li M, Sun Y, et al. A cell-penetrating peptide conjugated carboxymethyl-β-cyclodextrin to improve intestinal absorption of insulin. Int j biol macromol. 2018;111:685–695. doi: 10.1016/j.ijbiomac.2018.01.077
   PubMed Web of Science ®Google Scholar
• Hristov D, McCartney F, Beirne J, et al. Silica-coated nanoparticles with a core of zinc, l-arginine, and a peptide designed for oral delivery. ACS Appl Mater Interfaces. 2020;12(1):1257–1269. doi: 10.1021/acsami.9b16104
   PubMed Web of Science ®Google Scholar
• Li Y, Ji W, Peng H, et al. Charge-switchable zwitterionic polycarboxybetaine particle as an intestinal permeation enhancer for efficient oral insulin delivery. Theranostics. 2021;11(9):4452–4466. doi: 10.7150/thno.54176
   PubMed Web of Science ®Google Scholar
• Fox LJ, Richardson RM, Briscoe WH. PAMAM dendrimer - cell membrane interactions. Adv Colloid Interface Sci. 2018;257:1–18. doi: 10.1016/j.cis.2018.06.005
   PubMed Web of Science ®Google Scholar
• Lin Y, Fujimori T, Kawaguchi N, et al. Polyamidoamine dendrimers as novel potential absorption enhancers for improving the small intestinal absorption of poorly absorbable drugs in rats. J Control Release. 2011;149(1):21–28. doi: 10.1016/j.jconrel.2010.02.017
   PubMed Web of Science ®Google Scholar
• Yan C, Gu J, Lv Y, et al. Improved intestinal absorption of water-soluble drugs by acetylation of G2 PAMAM dendrimer nanocomplexes in rat. Drug Deliv Transl Res. 2017;7(3):408–415. doi: 10.1007/s13346-017-0373-8
   PubMed Web of Science ®Google Scholar
• Murgia X, Loretz B, Hartwig O, et al. The role of mucus on drug transport and its potential to affect therapeutic outcomes. Adv Drug Deliv Rev. 2018;124:82–97. doi: 10.1016/j.addr.2017.10.009
   PubMed Web of Science ®Google Scholar
• TM MW, Lau WM, Khutoryanskiy VV. Chitosan and its derivatives for application in mucoadhesive drug delivery systems. Polymers. 2018;10(3):267. doi: 10.3390/polym10030267
   PubMed Web of Science ®Google Scholar
• Duggan S, Cummins W, OD O, et al. Thiolated polymers as mucoadhesive drug delivery systems. Eur J Pharm Sci. 2017;100:64–78. doi: 10.1016/j.ejps.2017.01.008
   PubMed Web of Science ®Google Scholar
• Millotti G, Laffleur F, Perera G, et al. In vivo evaluation of thiolated chitosan tablets for oral insulin delivery. J Pharm Sci. 2014;103(10):3165–3170. doi: 10.1002/jps.24102
   PubMed Web of Science ®Google Scholar
• Chu JN, Traverso G. Foundations of gastrointestinal-based drug delivery and future developments. Nat Rev Gastroenterol Hepatol. 2022;19(4):219–238. doi: 10.1038/s41575-021-00539-w
   PubMed Web of Science ®Google Scholar
• Yamazoe E, Fang JY, Tahara K. Oral mucus-penetrating PEGylated liposomes to improve drug absorption: differences in the interaction mechanisms of a mucoadhesive liposome. Int J Pharm. 2021;593:120148. doi: 10.1016/j.ijpharm.2020.120148
   PubMed Web of Science ®Google Scholar
• Shan W, Zhu X, Tao W, et al. Enhanced oral delivery of protein drugs using zwitterion-functionalized nanoparticles to overcome both the diffusion and absorption barriers. ACS Appl Mater Interfaces. 2016;8(38):25444–25453. doi: 10.1021/acsami.6b08183
   PubMed Web of Science ®Google Scholar
• Han X, Lu Y, Xie J, et al. Zwitterionic micelles efficiently deliver oral insulin without opening tight junctions. Nat Nanotech. 2020;15(7):605–614. doi: 10.1038/s41565-020-0693-6
   PubMed Web of Science ®Google Scholar
• Uhl P, Pantze S, Storck P, et al. Oral delivery of vancomycin by tetraether lipid liposomes. Eur J Pharm Sci. 2017;108:111–118. doi: 10.1016/j.ejps.2017.07.013
   PubMed Web of Science ®Google Scholar
• Uhl P, Helm F, Hofhaus G, et al. A liposomal formulation for the oral application of the investigational hepatitis B drug Myrcludex B. Eur J Pharm Biopharm. 2016;103:159–166. doi: 10.1016/j.ejpb.2016.03.031
   PubMed Web of Science ®Google Scholar
• Parmentier J, Hofhaus G, Thomas S, et al. Improved oral bioavailability of human growth hormone by a combination of liposomes containing bio-enhancers and tetraether lipids and omeprazole. J Pharm Sci. 2014;103(12):3985–3993. doi: 10.1002/jps.24215
   PubMed Web of Science ®Google Scholar
• He Y, Huang Y, Xu H, et al. Aptamer-modified M cell targeting liposomes for oral delivery of macromolecules. Colloids Surf B Biointerfaces. 2023;222:113109. doi: 10.1016/j.colsurfb.2022.113109
   PubMed Web of Science ®Google Scholar
• Guo S, Liang Y, Liu L, et al. Research on the fate of polymeric nanoparticles in the process of the intestinal absorption based on model nanoparticles with various characteristics: size, surface charge and pro-hydrophobics. J Nanobiotechnology. 2021;19(1):32. doi: 10.1186/s12951-021-00770-2
   PubMed Web of Science ®Google Scholar
• Shi Y, Sun X, Zhang L, et al. Fc-modified exenatide-loaded nanoparticles for oral delivery to improve hypoglycemic effects in mice. Sci Rep. 2018;8(1):726. doi: 10.1038/s41598-018-19170-y
   PubMedGoogle Scholar
• Zhang L, Shi Y, Song Y, et al. Tf ligand-receptor-mediated exenatide-Zn(2+) complex oral-delivery system for penetration enhancement of exenatide. J Drug Target. 2018;26(10):931–940. doi: 10.1080/1061186X.2018.1455839
   PubMed Web of Science ®Google Scholar
• He H, Lu Y, Qi J, et al. Biomimetic thiamine- and niacin-decorated liposomes for enhanced oral delivery of insulin. Acta Pharm Sin B. 2018;8(1):97–105. doi: 10.1016/j.apsb.2017.11.007
   PubMed Web of Science ®Google Scholar
• Ren T, Zheng X, Bai R, et al. Utilization of PLGA nanoparticles in yeast cell wall particle system for oral targeted delivery of exenatide to improve its hypoglycemic efficacy. Int J Pharm. 2021;601:120583. doi: 10.1016/j.ijpharm.2021.120583
   PubMedGoogle Scholar
• Zhang X, Cheng H, Dong W, et al. Design and intestinal mucus penetration mechanism of core-shell nanocomplex. J Control Release. 2018;272:29–38. doi: 10.1016/j.jconrel.2017.12.034
   PubMed Web of Science ®Google Scholar
• Wu J, Zheng Y, Liu M, et al. Biomimetic viruslike and charge reversible nanoparticles to sequentially overcome mucus and epithelial barriers for oral insulin delivery. ACS Appl Mater Interfaces. 2018;10(12):9916–9928. doi: 10.1021/acsami.7b16524
   PubMed Web of Science ®Google Scholar
• Cheng H, Guo S, Cui Z, et al. Design of folic acid decorated virus-mimicking nanoparticles for enhanced oral insulin delivery. Int J Pharm. 2021;596:120297. doi: 10.1016/j.ijpharm.2021.120297
   PubMedGoogle Scholar
• Cao Y, Janjua TI, Qu Z, et al. Virus-like silica nanoparticles enhance macromolecule permeation in vivo. Biomater Sci. 2023;11(13):4508–4521. doi: 10.1039/D3BM00137G
   PubMed Web of Science ®Google Scholar
• Shen D, Yu H, Wang L, et al. Glucose-responsive nanoparticles designed via a molecular-docking-driven method for insulin delivery. J Control Release. 2022;352:527–539. doi: 10.1016/j.jconrel.2022.10.044
   PubMed Web of Science ®Google Scholar
• Hu WY, Wu ZM, Yang QQ, et al. Smart Ph-responsive polymeric micelles for programmed oral delivery of insulin. Colloids Surf B Biointerfaces. 2019;183:110443. doi: 10.1016/j.colsurfb.2019.110443
   PubMed Web of Science ®Google Scholar
• Yang T, Wang A, Nie D, et al. Ligand-switchable nanoparticles resembling viral surface for sequential drug delivery and improved oral insulin therapy. Nat Commun. 2022;13(1):6649. doi: 10.1038/s41467-022-34357-8
   PubMed Web of Science ®Google Scholar
• Shashni B, Tajika Y, Nagasaki Y. Design of enzyme-responsive short-chain fatty acid-based self-assembling drug for alleviation of type 2 diabetes mellitus. Biomaterials. 2021;275:120877. doi: 10.1016/j.biomaterials.2021.120877
   PubMed Web of Science ®Google Scholar
• Shan W, Zhu X, Liu M, et al. Overcoming the diffusion barrier of mucus and absorption barrier of epithelium by self-assembled nanoparticles for oral delivery of insulin. ACS Nano. 2015;9(3):2345–2356. doi: 10.1021/acsnano.5b00028
   PubMed Web of Science ®Google Scholar
• Sun L, Zhang XG, Wu ZM, et al. Oral glucose- and Ph-sensitive nanocarriers for simulating insulin release in vivo. Polym Chem. 2014;5(6):1999–2009. doi: 10.1039/C3PY01416A
   Web of Science ®Google Scholar
• Kaffash E, Shahbazi MA, Hatami H, et al. An insight into gastrointestinal macromolecule delivery using physical oral devices. Drug Discovery Today. 2022;27(8):2309–2321. doi: 10.1016/j.drudis.2022.04.014
   PubMed Web of Science ®Google Scholar
• Peng K, Shi Y, LaBarbiera A, et al. Mucoadhesive ionic liquid gel patches for oral delivery. ACS Biomater Sci Eng. 2023;9(6):2838–2845. doi: 10.1021/acsbiomaterials.0c01024
   PubMedGoogle Scholar
• Banerjee A, Chen R, Arafin S, et al. Intestinal iontophoresis from mucoadhesive patches: a strategy for oral delivery. J Control Release. 2019;297:71–78. doi: 10.1016/j.jconrel.2019.01.037
   PubMed Web of Science ®Google Scholar
• Abramson A, Caffarel-Salvador E, Khang M, et al. An ingestible self-orienting system for oral delivery of macromolecules. Science. 2019;363(6427):611–615. doi: 10.1126/science.aau2277
   PubMed Web of Science ®Google Scholar